Live
Funding 2 min read

Vitroscope raises USD 5 million in funding

Across multiple tracked sources led by Shifter, the reporting shows that Vitroscope raises USD 5 million in funding. The round adds a concrete capital signal to the current Nordic startup funding picture.

Image: Shifter

Vitroscope has successfully raised USD 5 million in a seed round led by Cerberus Ventures and YZR Capital. The Trondheim-based biotech company aims to commercialize its laboratory platform designed for keeping human tissue viable for longer periods. The seed funding brings the total capital raised, including $2 million from the Norwegian Research Council, to $8.8 million.

This round saw participation from Arcas Ventures, Golden Egg Check, and Devico Invest, along with various angel investors, including Carles Reina, Fàtima Godall, and Oskari Pétas. This infusion of capital will be directed towards commercializing the vitro.alive bench platform and validating its high-capacity version, vitro.scale. Vitroscope's technology tackles issues with traditional cell culture methods that limit the longevity of living tissue samples.

The company intends to start customer testing of vitro.scale in 2027, followed by a product launch the following year. This advancement could greatly enhance the capability of researchers to conduct experiments on living tissue under more realistic conditions.

Reporting sources

Where this story comes from

2 references

The facts above are grounded in the original reporting linked here. Open the publisher story for its complete context.

ShifterNO source · English rendering Open source

Vitroscope raises USD 5 million in funding

The available publisher preview does not add detail beyond this brief. Open the original report for its full context.

BootstrappingDA source · English rendering Open source

Vitroscope raises USD 5 million in funding

The available publisher preview does not add detail beyond this brief. Open the original report for its full context.

Related coverage

This story in context

Read the closer connections in publication order. Separate background links appear below.

You are reading this story

Later coverage 1

  1. Same event

    Norwegian startup secures $7 million to scale technology for studying living human tissue

    The review connects these reports to the same identifiable event. The source excerpts show the basis for the connection.

    ArcticStartup
    Why linked? View evidence
    Norwegian startup secures $7 million to scale technology for studying living human tissueRecorded source excerpt · original wording
    Trondheim-based biotech company Vitroscope has raised $7 million in a financing package comprising a $5 million seed round co-led by Cerberus Ventures and YZR Capital , alongside $2 million in non-dilutive funding from the Research Council of Norway . Arcas Ventures , Golden Egg Check , Devico Invest and angel investors Carles Reina , Fàtima Godall and Oskari Pétas also participated in the seed round .
    ArcticStartup ↗
    Vitroscope raises USD 5 million in fundingRecorded source excerpt · original wording
    Trondheim-baserte Vitroscope henter 5 millioner dollar i en såkornrunde ledet av Cerberus Ventures og YZR Capital. Kapitalen skal kommersialisere laboratorieplattformen for forskning på levende menneskevev. Ventureavdelingen til amerikanske Cerberus og europeiske YZR Capital leder såkornrunden i Trondheim-selskapet,...
    Shifter ↗
About this history review

The link graph’s cryptographic signature was verified. This proves integrity, not the truth of every claim or complete archive coverage.

Graph updated . Only articles retained in the public archive are included.

Open technical link data
Method & transparencyHow this brief was selected and checked
Editorial priority8 / 10

Priority

Source coverageMulti-source confirmation

2 source references

ConfidenceModerate

69 / 100

Source basis

Grounded in the publisher material listed below.

Confirmation

2 source references support this story.

Selection

Selected for publication after relevance, freshness and editorial-quality checks.

Selection factors

  • 2 independent sources
  • 2 concrete event indicators
  • editorial priority

Source monitoring: 98% recent availability · No source-health warnings. The original publisher remains the authoritative source for the full report.